91九色视频

header-logo
Research Group Lab Hall
Pharmacology and Toxicology
Michael Widlansky, MD, MPH

Michael E. Widlansky, MD, MPH

Northwestern Mutual Professor of Cardiovascular Medicine, Department of Medicine and Pharmacology; Director of the Cardiovascular Center

Contact Information

Education

MD, University of Michigan, 1999

Research Experience

  • Aging
  • Coronary Artery Disease
  • Diabetes Complications
  • Diabetes Mellitus, Type 2
  • endothelial function
  • Endothelium-Dependent Relaxing Factors
  • Exercise
  • Hypertension
  • Hypoglycemia
  • Nitric Oxide

Clinical Expertise

  • Coronary Artery Disease
  • Echocardiography

Methodologies and Techniques

  • arterial tonometry
  • digital pulse amplitude tonometry
  • flow mediate dilation
  • Microbubbles
  • Microscopy, Video
  • Plethysmography
  • Ultrasonography

Leadership Positions

  • Associate Fellowship Director, Cardiovascular Diseases
  • Chair, Human Research Affairs Committee
  • Member, Continuing Medical Education Committee
  • Member, Reserach Affairs Committee
  • Research Director, Division of Cardiovascular Medicine

91九色视频 Program / Core Facilities

  • Human Vascular Translational Reserach Core

Research Interests

The vascular endothelium, once thought to be a thin layer of quiescent cells present only to allow smooth, laminar blood flow has discovered to be a central regulator of vascular homeostasis. Both traditional and novel cardiovascular risk factors have been shown to induce the endothelium to take on a phenotype characterized by inflammation, pro-thrombotic stimuli, and vasoconstriction. This state of endothelial “dysfunction” has been shown to precede the development of atherosclerosis and portend cardiovascular events in both those with and without clinically evident cardiovascular disease. Endothelium-derived nitric oxide (EDNO) has been shown to be a central paracrine hormone in the maintenance of normal endothelial function, and a central characteristic of endothelial dysfunction is a reduction in bioavailable EDNO. Measuring EDNO bioavailability in larger conduit vessels and in the microvasculature in vivo can be accomplished by multiple modalities, including high-resolution vascular ultrasound and venous plethysmography. We employ these methodologies to investigate the pathophysiological mechanisms underlying the development of endothelial dysfunction in humans with a variety of disease states, including coronary artery disease and diabetes. Currently, we are investigating the role of disturbances in mitochondrial homeostasis in the modulation of vascular endothelial function in humans with Type II Diabetes. Many of our studies are small, clinical studies that apply different interventions to humans to assess their effects on vascular endothelial function, based on basic and animal work suggesting potential mechanisms for such a difference. Current protocols along this line include investigating the differential effects on vascular function of metformin and glipizide in Type II Diabetics. Our human vascular research laboratory has been formed to foster collaboration with investigators from other disciplines interested in the impact of vascular function on disease states relevant to their fields of interest. Current collaborative efforts include work with investigators from disciplines including Orthopedics, Dermatology, Geriatrics, Pediatric Endocrinology, and Pediatric Cardiology.

Publications

  • (Mahoney SA, VanDongen NS, Greenberg NT, Venkatasubramanian R, Rossman MJ, Widlansky ME, Brunt VE, Bernaldo de Quirós Y, Seals DR, Clayton ZS.) Am J Physiol Heart Circ Physiol. 2024 May 01;326(5):H1279-H1290 PMID: 38517225 PMCID: PMC11380963 SCOPUS ID: 2-s2.0-85191614683 03/22/2024

  • (Pandey R, Roberts ML, Wang J, Pereckas M, Jensen D, Greene AS, Widlansky ME, Liang M.) Lab Invest. 2024 May;104(5):102036 PMID: 38408704 PMCID: PMC11098693 SCOPUS ID: 2-s2.0-85189472781 02/27/2024

  • (Aljadah M, Khan N, Beyer AM, Chen Y, Blanker A, Widlansky ME.) JACC: Advances. August 2024;3(8) SCOPUS ID: 2-s2.0-85197318304 08/01/2024

  • (Widlansky ME, Liu Y, Tumusiime S, Hofeld B, Khan N, Aljadah M, Wang J, Anger A, Qiu Q, Therani B, Liu P, Liang M.) Circ Res. 2023 Sep;133(6):532-534 PMID: 37539553 PMCID: PMC10467803 SCOPUS ID: 2-s2.0-85169502007 08/04/2023

  • (Lamberg M, Devine A, Jewulski J, Smith A, Garster N, Sharma A, Mason PJ, Lewandowski D, Widlansky M, Mohananey D.) CASE (Phila). 2023 May;7(5):189-196 PMID: 37325463 PMCID: PMC10264206 06/16/2023

  • (SenthilKumar G, Katunaric B, Bordas-Murphy H, Young M, Doren EL, Schulz ME, Widlansky ME, Freed JK.) Am J Physiol Heart Circ Physiol. 2023 Mar 01;324(3):H330-H337 PMID: 36607795 PMCID: PMC9925162 SCOPUS ID: 2-s2.0-85147536237 01/07/2023

  • (Aljadah M, Widlansky ME.) Circ Res. 2023 Jan 20;132(2):182-184 PMID: 36656969 PMCID: PMC9869460 SCOPUS ID: 2-s2.0-85146623682 01/20/2023

  • (Egner JM, Nolden KA, Harwig MC, Bonate RP, De Anda J, Tessmer MH, Noey EL, Ihenacho UK, Liu Z, Peterson FC, Wong GCL, Widlansky ME, Hill RB.) J Biol Chem. 2022 Dec;298(12):102620 PMID: 36272645 PMCID: PMC9747602 SCOPUS ID: 2-s2.0-85143990858 10/23/2022

  • (Sommers N, Berger M, Rubenstein JC, Roth J, Pan A, Thompson C, Widlansky ME.) Eur Rev Aging Phys Act. 2022 Nov 02;19(1):26 PMID: 36324065 PMCID: PMC9628136 SCOPUS ID: 2-s2.0-85141077708 11/04/2022

  • (Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M.) Mol Ther. 2022 Nov 02;30(11):3462-3476 PMID: 35965413 PMCID: PMC9637778 SCOPUS ID: 2-s2.0-85136662053 08/16/2022

  • (Nolden KA, Egner JM, Collier JJ, Russell OM, Alston CL, Harwig MC, Widlansky ME, Sasorith S, Barbosa IA, Douglas AG, Baptista J, Walker M, Donnelly DE, Morris AA, Tan HJ, Kurian MA, Gorman K, Mordekar S, Deshpande C, Samanta R, McFarland R, Hill RB, Taylor RW, Oláhová M.) Life Sci Alliance. 2022 Aug 01;5(12) PMID: 35914810 PMCID: PMC9354038 SCOPUS ID: 2-s2.0-85135355811 08/02/2022

  • (Somayaji K, Frenkel M, Tabaza L, Visotcky A, Ruck TK, Ofori EK, Widlansky ME, Kulinski J.) Front Cardiovasc Med. 2022;9:869104 PMID: 35924212 PMCID: PMC9339901 SCOPUS ID: 2-s2.0-85135257452 08/05/2022

Publications of from the

© 2024 91九色视频.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.